BRKR
Bruker Corporation
Set alert
- YTD
- +21.14%
- 1 year
- +56.79%
- Open
- 59.47
- Prev close
- 62.00
- Mkt cap
- 8.70B
- Vol
- 1.92M
- Avg vol
- 2.30M
- EPS
- -0.70
- P/E
- 0.00
- Div yield
- 0.32%
More statistics
- Low
- 56.00
- High
- 60.17
- Forward P/E
- 23.75
- Beta
- 1.22
- Short ratio
- 5.27
- Inst. own
- 95.54%
- Dividend
- 0.20
- Ex-div date
- Sep 20, 2026
- Earnings
- Nov 4, 2026
- 50-d avg
- 58.96
- 200-d avg
- 50.18
- 1y target
- 63.83
Key statistics
- Market cap
- 8.70B
- Enterprise value
- 11.17B
- Trailing P/E
- 0.00
- Forward P/E
- 23.75
- PEG ratio
- 1.52
- Price / sales
- 2.48
- Price / book
- 3.65
- EPS (TTM)
- -0.70
- Beta
- 1.22
- Dividend yield
- 0.32%
- Payout ratio
- 38.46%
- Profit margin
- -2.04%
- Revenue (TTM)
- 3.50B
- Revenue growth
- 5.20%
- Free cash flow
- 179.94M
- Total cash
- 184.90M
- Total debt
- 1.86B
- Return on equity
- -3.00%
- Shares outstanding
- 152.36M
- Short % of float
- 16.03%
- 50-day average
- 58.96
- 200-day average
- 50.18
Analyst view
Consensus: buy
- Target (low)
- 50.00
- Target (mean)
- 63.83
- Target (high)
- 80.00
- Strong buy1
- Buy5
- Hold6
- Sell1
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.41601.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.4188 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | 0.3849 | 0.49 | +0.11 | +27.31% |
| May 6, 2026 | Mar 31, 2026 | 0.23 | 0.31 | +0.08 | +34.78% |
| Feb 12, 2026 | Dec 31, 2025 | 0.65 | 0.59 | -0.06 | -9.23% |
| Nov 3, 2025 | Sep 30, 2025 | 0.33 | 0.60 | +0.27 | +81.82% |
| Aug 4, 2025 | Jun 30, 2025 | 0.33 | 0.32 | -0.01 | -3.03% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2026 | JP Morgan | down | Overweight | Neutral |
| Oct 13, 2026 | TD Cowen | main | Hold | Hold |
| Oct 7, 2026 | Barclays | main | Overweight | Overweight |
| Oct 1, 2026 | Guggenheim | main | Buy | Buy |
| Sep 29, 2026 | Leerink Partners | main | Outperform | Outperform |
| Sep 9, 2026 | UBS | main | Neutral | Neutral |
About Bruker Corporation
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bruker.com
News
- SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today
- Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast
- Is Bruker Corp (BRKR) a Bargain After 3.1% Drop? GF Value Says Undervalued
- This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
- JP Morgan Downgrades Bruker to Neutral, Announces $60 Price Target
- TD Cowen Maintains Hold on Bruker, Raises Price Target to $62
- Bruker Gains 66.3% in a Year: What's Driving the Rally?
- Barclays Maintains Overweight on Bruker, Raises Price Target to $70
- Bruker Corp (BRKR) Shares Fall 5.3% -- GF Value Says Still Overvalued
- Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution
Your note
Sign in to keep a note on BRKR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BUSSE FALKO | Officer | Stock Award(Grant) | Aug 14, 2025 | 48,171 |
| HERMAN GERALD N | Chief Financial Officer | Stock Award(Grant) | Aug 13, 2026 | 111,354 |
| LAUKIEN FRANK H | Chief Executive Officer | Stock Award(Grant) | Aug 13, 2026 | 40,511,100 |
| LINTON WILLIAM A. | Director | Stock Award(Grant) | Feb 12, 2026 | 63,243 |
| MUNCH MARK ROBERT | Officer | Conversion of Exercise of derivative security | Sep 14, 2026 | 134,806 |
| ORNELL JOHN A | Director | Stock Award(Grant) | Feb 12, 2026 | 39,732 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 13.28% | 20,237,425 | 1.15B | Jun 29, 2026 |
| Orbis Allan Gray Ltd | 11.77% | 17,940,076 | 1.02B | Jun 29, 2026 |
| Blackrock Inc. | 7.49% | 11,407,332 | 651.02M | Jun 29, 2026 |
| Pallas Capital Advisors Llc | 6.22% | 9,483,978 | 541.25M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.21% | 4,888,290 | 278.97M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.19% | 4,859,252 | 277.32M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 2.60% | 3,961,759 | 226.10M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.22% | 3,380,103 | 192.90M | Jun 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1.87% | 2,848,282 | 162.55M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.60% | 2,444,714 | 139.52M | Jun 29, 2026 |
| Fidelity Hastings Street Trust-Fidelity Series Large Cap Stock Fund | 1.55% | 2,358,800 | 134.62M | Aug 30, 2026 |
| Touchstone Fd.s Group TRT-Touchstone Fd.s Group TRT-Touchstone Mid Cap | 1.26% | 1,919,283 | 109.53M | Jun 29, 2026 |